About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Israel Fernández Cadenas, principal investigator of the Pharmacogenomics and Stroke Genetics Laboratory at the Sant Pau Research Institute.
Abstract: We will discuss how genomics, epigenomics, proteomics and transcriptomics are useful to understand the biological architecture of complex diseases and find treatments or drug targets for these diseases. Nowadays there is a lot of big data available that can be very useful for translational research. We will show some examples in stroke of how we can analyze this data to find treatments and drug targets to improve stroke outcome that can be applied for other pathologies.
Host: Dr. Mar Hernández Guillamón, Main researcher Neurovascular Diseases. Vall d'Hebron Research Institute (VHIR)
Online attendance: https://gencat.zoom.us/j/85661291449
